Anti-IL-2 mAb activates Tregs to treat autoimmune diseases

In a paper published in Nature Medicine, scientists generated a human mAb against IL-2 that preferentially activates Tregs and could help treat autoimmune diseases.

Previous studies have shown that low doses of IL-2 can help treat autoimmune diseases and graft-versus-host disease (GvHD). However, IL-2 binds and activates IL-2 receptors on both immunosuppressive Tregs and effector T cells that exacerbate disease, which can result in off-target effects for IL-2 therapy. ...